Mostrar el registro sencillo del ítem

dc.date.accessioned2024-12-06T16:51:43Z
dc.date.available2024-12-06T16:51:43Z
dc.date.issued2024-09-19es_MX
dc.identifier.urihttps://cathi.uacj.mx/20.500.11961/29362
dc.description.abstractAnimal venoms are natural products that have served as a source of novel molecules that have inspired novel drugs for several diseases, including for metabolic diseases such as type-2 diabetes and obesity. From venoms, toxins such as exendin-4 (Heloderma suspectum) and crotamine (Crotalus durissus terrificus) have demonstrated their potential as treatments for obesity. Moreover, other toxins such as Phospholipases A2 and Disintegrins have shown their potential to modulate insulin secretion in vitro. This suggests an unexplored diversity of venom peptides with a potential anti-obesogenic in Mexican rattlesnake venoms. For that reason, this study explored the in vitro effect of Crotalus venom peptide-rich fractions on models for insulin resistance, adipocyte lipid accumulation, antioxidant activity, and inflammation process through nitric oxide production inhibition. Our results demonstrated that the peptide-rich fractions of C. aquilus, C. ravus, and C. scutulatus scutulatus were capable of reverting insulin resistance, enhancing glucose consumption to normal control; C. culminatus, C. molossus oaxacus, and C. polystictus diminished the lipid accumulation on adipocytes by 20%; C. aquilus, C. ravus, and C. s. salvini had the most significant cellular antioxidant activity, having nearly 80% of ROS inhibition. C. aquilus, C. pyrrhus, and C. s. salvini inhibited nitric oxide production by about 85%. We demonstrated the potential of these peptides from Crotalus venoms to develop novel drugs to treat type-2 diabetes and obesity. Moreover, we described for the first time that Crotalus venom peptide fractions have antioxidant and inflammatory properties in vitro models.es_MX
dc.description.urihttps://www.sciencedirect.com/science/article/pii/S2590171024000262es_MX
dc.language.isoen_USes_MX
dc.relation.ispartofProducto de investigación ICBes_MX
dc.relation.ispartofInstituto de Ciencias Biomédicases_MX
dc.subjectAdipocyte lipid accumulationes_MX
dc.subjectBioactive peptideses_MX
dc.subjectCrotaluses_MX
dc.subjectInsulin resistancees_MX
dc.subjectVenomes_MX
dc.subjectCrotamine-like peptideses_MX
dc.subject.otherinfo:eu-repo/classification/cti/2es_MX
dc.titleBioprospection of rattlesnake venom peptide fractions with anti-adipose and anti-insulin resistance activity in vitroes_MX
dc.typeArtículoes_MX
dcterms.thumbnailhttp://ri.uacj.mx/vufind/thumbnails/rupiicb.pnges_MX
dcrupi.institutoInstituto de Ciencias Biomédicases_MX
dcrupi.cosechableSies_MX
dcrupi.norevista100209es_MX
dcrupi.volumen24es_MX
dcrupi.nopagina1-11es_MX
dc.identifier.doihttps://doi.org/10.1016/j.toxcx.2024.100209es_MX
dc.contributor.coauthorGatica Colima, Ana Bertha
dc.contributor.coauthorPlenge Tellechea, Luis Fernando
dc.journal.titleToxicon: Xes_MX
dc.contributor.authorexternoMeléndez-Martínez, David
dc.contributor.coauthorexternoOrtega-Hernández, Erika
dc.contributor.coauthorexternoReza-Zaldivar, Edwin Estefan
dc.contributor.coauthorexternoCarbajal-Sauced, Alejandro
dc.contributor.coauthorexternoArnaud-Franco, Gustavo
dc.contributor.coauthorexternoAntunes-Ricardo, Marilena
dc.contributor.coauthorexternoJacobo-Velázquez, Daniel A.
dc.contributor.coauthorexternoMayolo-Deloisa, Karla
dc.contributor.coauthorexternoLozano, Omar
dc.contributor.coauthorexternoRito-Palomares, Marco
dc.contributor.coauthorexternoBenavides, Jorge
dcrupi.impactosocialTiene impacto porque los resultados pueden contribuir como base en la obtención de productos farmacológicos para atender problemas de salud como obesidad y diabeteses_MX
dcrupi.vinculadoproyextCONAHCYT CIencia en la Frontera 2023 (CF-2023-I-2019)es_MX
dcrupi.pronacesSaludes_MX


Archivos en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem


Av. Plutarco Elías Calles #1210 • Fovissste Chamizal
Ciudad Juárez, Chihuahua, México • C.P. 32310 • Tel. (+52) 688 – 2100 al 09